Literature DB >> 12851245

Current epidemiology of septic shock: the CUB-Réa Network.

Djillali Annane1, Philippe Aegerter, Marie Claude Jars-Guincestre, Bertrand Guidet.   

Abstract

To update the epidemiology of septic shock we analyzed clinical, microbiologic, and outcome variables from 100,554 intensive care unit admissions on the Collège des Utilisateurs de Bases de données en Réanimation (CUB-Réa) database, collected from 22 hospitals over a 8-year period, 1993 to 2000. The overall frequency of septic shock was 8.2 per 100 admissions (i.e., 8,251 stays). It increased from 7.0 (in 1993) to 9.7 per 100 admissions (in 2000). The distribution analysis of the sites of infection and of the types of pathogens showed an increase in the rate of pulmonary infection (p = 0.001) and of multiresistant bacteria-related septic shock (p = 0.001). The crude mortality was 60.1% and declined from 62.1% (in 1993) to 55.9 (in 2000) (p = 0.001). As compared with matched intensive care unit admissions without sepsis, the excess risk of death due to septic shock was 25.7 (95% confidence interval, 24.0-27.3) and the matched odds ratio of death was 3.9 (95% confidence interval, 3.5-4.3). The frequency of septic shock is increasing with more multiresistant strains. Its crude mortality rate is decreasing, but patients with septic shock still have a high excess risk of death than critically ill patients who are nonseptic.

Entities:  

Mesh:

Year:  2003        PMID: 12851245     DOI: 10.1164/rccm.2201087

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN: 1073-449X            Impact factor:   21.405


  191 in total

Review 1.  Corticosteroids for severe sepsis and septic shock: a systematic review and meta-analysis.

Authors:  Djillali Annane; Eric Bellissant; Pierre Edouard Bollaert; Josef Briegel; Didier Keh; Yizhak Kupfer
Journal:  BMJ       Date:  2004-08-02

Review 2.  [Shock--what are the basics?].

Authors:  U Janssens; J Graf
Journal:  Internist (Berl)       Date:  2004-03       Impact factor: 0.743

3.  Activated protein C in patients with septic shock: a consecutive case series.

Authors:  Jens A Wagner; Heiner Langenfeld; Luise Klett; Stefan Störk
Journal:  Int J Clin Pharm       Date:  2011-11-27

4.  Pulmonary microvascular hyperpermeability and expression of vascular endothelial growth factor in smoke inhalation- and pneumonia-induced acute lung injury.

Authors:  Matthias Lange; Atsumori Hamahata; Daniel L Traber; Rhykka Connelly; Yoshimitsu Nakano; Lillian D Traber; Frank C Schmalstieg; David N Herndon; Perenlei Enkhbaatar
Journal:  Burns       Date:  2012-05-29       Impact factor: 2.744

5.  Renal failure in septic shock: predictive value of Doppler-based renal arterial resistive index.

Authors:  Nicolas Lerolle; Emmanuel Guérot; Christophe Faisy; Caroline Bornstain; Jean-Luc Diehl; Jean-Yves Fagon
Journal:  Intensive Care Med       Date:  2006-08-29       Impact factor: 17.440

6.  Incidence of sepsis in hospitalized patients.

Authors:  Rui Moreno; Susana Afonso; Teresa Fevereiro
Journal:  Curr Infect Dis Rep       Date:  2006-09       Impact factor: 3.725

7.  Angiotensin-converting enzyme inhibitor/angiotensin II receptor blocker use prior to medical intensive care unit admission and in-hospital mortality: propensity score-matched cohort study.

Authors:  Daiki Kobayashi; Nagato Kuriyama; Fumitaka Yanase; Osamu Takahashi; Kazuhiro Aoki; Yasuhiro Komatsu
Journal:  J Nephrol       Date:  2019-04-01       Impact factor: 3.902

8.  Sepsis-induced inflammation is exacerbated in an animal model of type 2 diabetes.

Authors:  Asha Jacob; Marissa L Steinberg; Juntao Yang; Weifeng Dong; Youxin Ji; Ping Wang
Journal:  Int J Clin Exp Med       Date:  2008-01-10

9.  Epidemiology of sepsis: recent advances.

Authors:  Pajman Danai; Greg S Martin
Journal:  Curr Infect Dis Rep       Date:  2005-09       Impact factor: 3.725

Review 10.  Improving the Recognition of, and Response to In-Hospital Sepsis.

Authors:  Peter Chan; Sandra Peake; Rinaldo Bellomo; Daryl Jones
Journal:  Curr Infect Dis Rep       Date:  2016-07       Impact factor: 3.725

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.